Investors

As a late clinical-stage biopharmaceutical company focused on oncology, our business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

Our lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, and has reported positive results from a pre-planned pharmacoeconomic study. These outstanding results support the goal of Motixafortide becoming the standard of care mobilization agent in autologous bone-marrow transplantation, and in this regard we are currently preparing an NDA submission.read more

 

Upcoming Events View all

There are currently no events to display.

I.R. Contacts

If you would like further information or have questions or comments, please contact:

Tim McCarthy
LifeSci Advisors, LLC
+1-212-915-2564
tim@lifesciadvisors.com

Media inquiries:

Moran Meir
LifeSci Advisors, LLC
+972-54-476-4945
moran@lifesciadvisors.com